<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology and molecular mechanisms of drug-resistant tuberculosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology and molecular mechanisms of drug-resistant tuberculosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology and molecular mechanisms of drug-resistant tuberculosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Neil W Schluger, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Bernardo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tuberculosis (TB) remains one of the leading causes of morbidity and mortality worldwide, and resistance to commonly used antituberculous drugs is increasing.</p><p>Drug-resistant TB was recognized shortly after the introduction of effective chemotherapy in the late 1940s. <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">Streptomycin</a> was the first drug to be used widely. Patients who received this drug usually had marked and rapid clinical improvement, but treatment failures were common after the first three months of therapy. Isolates of <em>Mycobacterium tuberculosis</em> obtained from patients with treatment failure were invariably streptomycin resistant. The rapid development of resistance to single-agent therapy led to the principle of multiagent chemotherapy of TB that remains the cornerstone of treatment.</p><p>The epidemiology and molecular basis of drug-resistant TB will be reviewed here. The diagnosis and treatment of drug-resistant strains of <em>M. tuberculosis</em> are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults"</a>.)</p><p class="headingAnchor" id="H2700798617"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>TB terminology is inconsistent in the literature [<a href="#rid1">1</a>]. Relevant terms are defined in the table  (<a class="graphic graphic_table graphicRef132526" href="/z/d/graphic/132526.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS FOR TUBERCULOSIS DRUG RESISTANCE</span><span class="headingEndMark"> — </span>Definitions for drug-resistant TB are summarized in the table  (<a class="graphic graphic_table graphicRef138279" href="/z/d/graphic/138279.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H4"><span class="h2">Drug-resistant tuberculosis</span></p><p class="headingAnchor" id="H6"><span class="h3">Worldwide</span><span class="headingEndMark"> — </span>Precise information about the global incidence of drug-resistant TB is difficult to obtain, since routine sputum culture and drug susceptibility testing are not performed routinely in all resource-limited settings, where the disease occurs most frequently [<a href="#rid2">2</a>]. However, this situation has improved somewhat; data on drug resistance have been systematically collected from more than 160 countries by the World Health Organization (WHO), representing more than 99 percent of the global population and TB cases. In addition, a major advancement in surveillance of drug resistance has been uptake of molecular detection methods, which allow continuous monitoring of the prevalence of drug resistance (particularly <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> resistance) in many high-burden countries  (<a class="graphic graphic_table graphicRef111123" href="/z/d/graphic/111123.html" rel="external">table 3</a>). </p><p>The WHO 2021 Global Tuberculosis Report noted that globally in 2020, more than 157,000 people were diagnosed with rifampin-resistant, multidrug-resistant (MDR), or extensively-resistant TB. This was a dramatic drop from the more than 201,000 people diagnosed in 2019; the decline almost certainly represents the difficulties in maintaining surveillance activities during the coronavirus disease 2019 (COVID-19) pandemic than it does any successes in controlling the spread of drug-resistant TB. This drop is mirrored by an overall decline of 17 percent in cases of TB overall globally in 2020. </p><p>The WHO 2020 Global Tuberculosis Report had estimated that, worldwide, approximately 3.3 percent of all new TB cases and 18 percent of previously treated cases are caused by MDR or rifampin-monoresistant strains [<a href="#rid3">3</a>]. Worldwide surveys indicate that drug-resistant TB is a large problem, although the overall burden of MDR-TB relative to the number of new and treated cases is relatively stable  (<a class="graphic graphic_figure graphicRef116433" href="/z/d/graphic/116433.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef116434" href="/z/d/graphic/116434.html" rel="external">figure 2</a>) [<a href="#rid4">4,5</a>]. </p><p>In 2019, the WHO estimated that there were roughly 465,000 cases of incident MDR-TB worldwide [<a href="#rid6">6</a>]; it is estimated that 214,000 deaths from MDR-TB occurred in 2017 [<a href="#rid6">6</a>]. This number likely rose in 2020 because of the impact of COVID-19 pandemic on TB control efforts. Globally, only 71 percent of individuals with bacteriologically confirmed TB were tested for <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> resistance, although this represents remarkable progress over the last decade; in 2017, only 51 percent were tested, and that figure represents a tremendous increase from 2012, when the figure was only 7 percent. Only about 61 percent of cases of TB in the world were bacteriologically confirmed, so in absolute terms, substantially fewer than half of all individuals with TB are tested for drug resistance [<a href="#rid7">7</a>].</p><p>MDR-TB occurs worldwide; China, India, Russia, and the countries of the former Soviet Union are estimated to carry the highest number of MDR-TB cases [<a href="#rid4">4,5,8-16</a>], while the highest proportion of MDR cases are still seen in several countries of the former Soviet Union. Of patients who received treatment, overall outcomes were poor; only about 56 percent of patients were considered cured. As improved diagnostic testing becomes available, MDR-TB will likely be recognized as the major threat to global TB control over the next several decades.</p><p>The highest-burden countries for MDR-TB include many countries of the former Soviet Union (Kazakhstan, Azerbaijan, Belarus, Moldova, Uzbekistan, Tajikistan, Ukraine, Kyrgyzstan), several Africa countries (Angola, the Democratic Republic of Congo, Mozambique, Nigeria, South Africa, Somalia, Zambia and Zimbabwe), and several Asian nations (Indonesia, Pakistan, Mongolia, Nepal, Philippines, and Bangladesh).</p><p>Many MDR cases are reported in individuals who have not received prior treatment; however, a history of prior treatment (especially if incomplete or unsupervised) is an important risk factor for the presence of MDR-TB in a given patient. However, it is increasingly recognized that the dominant mode of development of MDR-TB is transmission rather than the development of de novo resistance in patients under treatment. The presence of initial drug resistance substantially reduces treatment outcomes, since in general, most TB treatment approaches rely on standardized rather than tailored treatment regimens [<a href="#rid17">17,18</a>]. In one study including data from 103 countries where standardized regimens are used, failure and relapse rates were significantly higher in regions where the initial multidrug-resistance prevalence was ≥3 percent [<a href="#rid18">18</a>]. In these areas, retreatment was required in more than 20 percent of cases. High rates of MDR-TB among patients requiring retreatment have also been described; in one survey from the Philippines, MDR-TB was observed 76 percent of retreatment cases [<a href="#rid19">19</a>].</p><p>According to the WHO 2020 Global TB Report, rates of MDR-TB are increasing in Russia, Ukraine, and Peru. In other countries with a high burden of TB and MDR-TB, the rate of decline in MDR incidence is substantially below that of cases of drug susceptible disease.</p><p>Some resistance data for other countries in Africa have been reported. In Botswana, the rate of drug resistance is increasing, despite implementation of 100 percent coverage of directly observed therapy short course (DOTS) strategy in 1986. In a 2002 survey of drug resistance among isolates from 1182 patients with newly diagnosed TB, rates of monoresistance and MDR-TB were 10.4 and 0.8 percent, respectively [<a href="#rid20">20</a>]. Among 106 patients previously treated for TB, the respective rates were 22.8 and 10.4 percent. In Uganda, the burden of drug resistance in previously treated patients with TB is also sizeable. Among 410 patients enrolled between 2003 and 2006, the prevalence of MDR-TB was 12.7 percent [<a href="#rid21">21</a>]. A survey of resistance to <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">pyrazinamide</a> and quinolones in Africa, Asia, and Eastern Europe found varying rates of resistance across these regions; resistance was quite high in some areas [<a href="#rid22">22</a>].</p><p>The outcome of DOTS with a standard four-drug regimen was evaluated by the WHO retrospectively in six geographically distinct countries [<a href="#rid23">23</a>]. Not surprisingly, treatment failures were higher among new MDR-TB cases than among new susceptible cases (10 versus 0.7 percent).</p><p class="headingAnchor" id="H7697855"><span class="h3">United States</span><span class="headingEndMark"> — </span>Substantial drug resistance began emerging in regions of the United States in the early 1990s [<a href="#rid24">24,25</a>]. The prevalence of drug-resistant TB in the United States decreased between 1991 and 2006 (3.5 to 1.1 percent) and remained stable between 2005 and 2006 (1.2 percent), even as drug-resistant disease increased worldwide [<a href="#rid26">26,27</a>]. About 12.6 percent of drug-resistant TB cases in the United States can be linked to domestic transmission [<a href="#rid28">28</a>]. Adherence to hospital infection control measures, the widespread use of an initial four-drug chemotherapy regimen, and directly observed therapy are critical for controlling the incidence rates of drug-resistant TB in the United States [<a href="#rid27">27,29-31</a>].</p><p>Single-drug resistance to <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> (the most common form of drug resistance in the United States) occurred in approximately 9.6 percent of cases with positive cultures in 2019, an increase from 8.4 percent of cases in 2006 [<a href="#rid32">32</a>]. The percentage of TB cases that are isoniazid resistant has risen slowly but consistently for several years [<a href="#rid33">33</a>]. In 2019, the percentage of isoniazid (INH) resistance was higher among previously treated cases than untreated cases (14 versus 9 percent). INH resistance is slightly higher among individuals born outside the United States than among individuals born within the United States. The rate is variable by region; rates of INH resistance ranged from 0 to 34 percent [<a href="#rid34">34</a>]. In 2020, only 213 (6.3 percent) of reported cases of TB in the United States were found to be INH resistant.  </p><p>Multidrug resistance has decreased overall between 1993 and 2019 (2.4 to 1.3 percent) [<a href="#rid35">35</a>]. MDR-TB disproportionately affects foreign-born individuals; this group accounted for 85 percent of cases of MDR-TB in 2019 [<a href="#rid27">27</a>]. MDR-TB cases accounted for 0.6 percent of cases occurring in individuals born in the United States and 1.6 percent of individuals born outside the United States [<a href="#rid34">34</a>]. In 2020, the number of MDR-TB cases reported in the United States fell to 213 (from 272 in 2019); it is difficult to know how much (if any) of this decrease was real or merely a reflection of the reduced surveillance efforts during the COVID-19 pandemic.</p><p>Migration of individuals with TB can alter the prevalence and resistance patterns. Among 10,000 Hmong refugees resettled from Thailand into the United States from June 2004 through January 2005, 37 were found to have active TB, including 4 with MDR-TB [<a href="#rid36">36</a>]. Among the 6000 refugees still awaiting emigration from Thailand, TB was identified in 6 percent of individuals; of these, MDR-TB was observed in 6 percent of cases, half of which were smear negative [<a href="#rid37">37</a>]. As a result, enhanced screening for all immigrants and refugees entering the United States was implemented by the Centers for Disease Control, beginning with high-priority countries as determined by TB prevalence and immigration patterns.</p><p>At the peak of the human immunodeficiency virus (HIV) epidemic in the United States, HIV infection was associated with MDR-TB [<a href="#rid24">24</a>]. Subsequently, a 2007 review of published studies and surveillance data noted that MDR-TB does not appear to cause infection or disease in individuals with HIV infection more readily than drug-susceptible strains, although HIV infection and MDR-TB may converge in some countries [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Extensively drug-resistant tuberculosis</span><span class="headingEndMark"> — </span>The epidemiology of extensively drug-resistant TB is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8004.html" rel="external">"Epidemiology of extensively drug-resistant tuberculosis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">RISK FACTORS FOR DEVELOPMENT OF DRUG RESISTANCE</span><span class="headingEndMark"> — </span>Risk factors for multidrug-resistant TB (MDR-TB) are summarized in the following table  (<a class="graphic graphic_table graphicRef108729" href="/z/d/graphic/108729.html" rel="external">table 4</a>); these include prior episodes of TB treatment, progressive clinical and/or radiographic findings while on TB therapy, residence in or travel to a region with high prevalence of drug-resistant TB  (<a class="graphic graphic_figure graphicRef116433" href="/z/d/graphic/116433.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef116434" href="/z/d/graphic/116434.html" rel="external">figure 2</a>), and/or exposure to an individual with known or suspected infectious drug-resistant TB.</p><p>Each patient with TB harbors a mixed population of organisms with naturally occurring resistance to various drugs. Such resistance occurs by spontaneous mutation within the organism's genome as they replicate. Selection for these resistant organisms will occur if only one drug is used in treatment, since approximately 1 in 10<sup>6</sup> to 10<sup>8</sup> organisms exhibits intrinsic resistance to any given drug. The chance that an organism in a population is resistant to two drugs is roughly 1 in 10<sup>14</sup>, making resistance much less likely to emerge with combination therapy. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a>.)</p><p>The development of MDR-TB is favored by an inadequate course of treatment. MDR cases in the United States are uncommon; development of MDR-TB in the United States may reflect poor prescribing practices, poorly supervised treatment, and poor infection control in hospitals and prisons. However, it is also likely that as MDR cases have proliferated worldwide, cases in the United States may represent reactivation of latent infection caused by drug-resistant strains acquired prior to immigration. </p><p>The global burden of MDR-TB is large (roughly half a million individuals) and is almost completely uncontrolled. The WHO estimates that no more than 20 percent of individuals with MDR-TB are diagnosed or treated, and of those that are treated, the outcome is favorable in only slightly more than half of cases. This means that there are many patients with MDR-TB who are likely to be infectious for prolonged periods. In addition, the global HIV epidemic has fueled spread of MDR-TB in places like South Africa by creating a large reservoir of immunosuppressed individuals who are more likely to develop active TB disease following infection. </p><p>In general, the acquisition of drug resistance is thought to come at a cost of overall fitness; MDR strains are not thought to be more virulent or transmissible. However, one molecular epidemiology study from China reported that MDR strains were more transmissible than drug-susceptible strains [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/8018.html" rel="external">"Epidemiology of tuberculosis"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Inappropriate therapy</span><span class="headingEndMark"> — </span>The American Thoracic Society/United States Centers for Disease Control and Prevention (ATS/CDC) guideline published in 1994 recommended initial treatment with four-drug therapy in areas where the rate of <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> resistance exceeds 4 percent [<a href="#rid40">40</a>]. Nonetheless, one 1995 report noted that approximately 25 percent of new TB cases were initially treated with two or three drug regimens [<a href="#rid30">30</a>].</p><p>Prescribing errors by physicians inexperienced in the care of patients with TB can exacerbate problems associated with drug resistance. One review of patients referred to the National Jewish Hospital in Denver for management of complex MDR-TB noted an average of nearly four prescribing errors per patient [<a href="#rid41">41</a>]. This highlights the need for expert management of drug-resistant TB in all cases.</p><p class="headingAnchor" id="H12"><span class="h2">Compliance</span><span class="headingEndMark"> — </span>One study in New York City documented that patients with high rates of alcohol and drug abuse discharged from the hospital were unlikely to adhere to TB treatment regimens; among 178 patients, only 11 percent complied with therapy [<a href="#rid42">42</a>]. Drugs were taken erratically and often singly, making the emergence of drug resistance more likely.</p><p>In communities with long-standing programs of supervised or directly observed therapy (DOT), such as Baltimore, Maryland, or Tarrant County, Texas, drug resistance has not emerged as a serious problem [<a href="#rid43">43,44</a>]. Furthermore, the incidence of MDR-TB diminished in New York after DOT was implemented [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/8019.html" rel="external">"Adherence to tuberculosis treatment"</a>.)</p><p class="headingAnchor" id="H19584302"><span class="h2">Patient characteristics</span><span class="headingEndMark"> — </span>Individual differences in the pharmacokinetics (including absorption, disposition, and elimination of a drug) may lead to development of drug resistance [<a href="#rid46">46,47</a>]. A given dose does not lead to identical concentration-time profiles in all patients, and pharmacokinetic variability to a single drug in a regimen is significantly associated with failure of therapy in patients with acquired drug resistance [<a href="#rid47">47</a>]. The concentration achieved by a particular dose is determined in part by patient physiology, gene alleles encoding enzymes involved in drug metabolism, dietary considerations, concomitant drug administration, and comorbidities [<a href="#rid48">48</a>]. Clinical trial simulations suggest that 1 percent of TB patients with perfect adherence may develop MDR-TB due to pharmacokinetic variability alone [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H19584283"><span class="h2">Strain characteristics</span><span class="headingEndMark"> — </span>Propagation of drug-resistant strains appears to depend on both their fitness and diversity [<a href="#rid49">49</a>]. The risk of infection with drug-resistant strains may be amplified in regions where there is reduced cross-immunity between originating strain groups. However, epidemiologic studies and TB vaccine trials indicate that cross-protective immunity to TB can be conferred by infection within the <em>M. tuberculosis</em> complex (eg, by <em>Mycobacterium bovis</em>, <em>Mycobacterium microti</em>) as well as by infection within the entire genus (eg, by nontuberculous mycobacteria), suggesting that antigens common to all organisms within the genus may play a dominant role in immune protection against human TB [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Nosocomial transmission and HIV</span><span class="headingEndMark"> — </span>Several nosocomial outbreaks of MDR-TB have been reported, primarily from hospitals and prisons in New York and New Jersey [<a href="#rid51">51-54</a>]. Most of the cases occurred in individuals with HIV infection, and reported mortality is high in all series. Links between cases were found by contact tracing and confirmed using molecular biologic techniques. Restriction fragment length polymorphism (RFLP) analysis, also known as deoxyribonucleic acid (DNA) fingerprinting, can determine the clonal origin of organisms responsible for a case cluster; clonality implies transmission of TB between cases or infection from a common index case.</p><p>Genotyping of MDR-TB case-clusters has demonstrated spread among patients with HIV infection with apparently trivial exposure when proper isolation and infection control measures are not enforced [<a href="#rid51">51-54</a>]. A hierarchy of control measures has been employed to improve infection control practices in hospitals, nursing homes, and other congregate facilities. These include isolation of suspected TB cases, rapid examination of sputum smears, health care worker use of particulate respirators, and use of environmental measures such as germicidal ultraviolet irradiation, high-efficiency particulate air filters, frequent air exchanges, and negative pressure ventilation. These measures, if applied properly, may decrease transmission and nosocomial infection [<a href="#rid55">55-57</a>]. (See  <a class="medical medical_review" href="/z/d/html/8000.html" rel="external">"Tuberculosis transmission and control in health care settings"</a>.)</p><p>In many poor countries, these infection control measures are not affordable. Furthermore, isolation of patients is impossible because of the volume of cases. Patients are often kept together in large open wards, creating significant problems with nosocomial transmission [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H15"><span class="h1">MOLECULAR BASIS OF DRUG-RESISTANT TUBERCULOSIS</span><span class="headingEndMark"> — </span>Our understanding of the molecular basis for drug resistance in <em>M. tuberculosis</em> is improving. This knowledge is important for new drug design, development of new rapid diagnostic tools for case-tailored therapy based on specific drug resistance in the individual patient, and creating new therapeutic strategies against drug-resistant TB.</p><p>The GeneXpert system for nucleic acid amplification testing of sputum for MTb Complex DNA and molecular detection of resistance to <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> was approved by the US Food and Drug Administration (FDA) in 2013 and is available in many United States public health and hospital laboratories. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p>In addition, the United States Centers for Disease Control and Prevention (CDC) TB laboratory performs rapid molecular testing for drug resistance for first-line and many second-line drugs on sputum sediments and isolates of MTb Complex. This service assists clinicians and public health programs in the management of potentially drug-resistant cases and contacts [<a href="#rid59">59,60</a>]. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults", section on 'Molecular testing'</a>.)</p><p>Molecular tests may have false-negative or false-positive results; individual data must be interpreted in the clinical context and confirmed using culture methods for isolation, identification, and drug susceptibility testing. Even in low-prevalence settings, where the proportion of false-positive cases to true-positive cases might be assumed to be higher than in high-prevalence settings, use of GeneXpert in diagnostic algorithms appears to result in significant reduction in unnecessary treatment as compared with standard clinical approaches [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Isoniazid resistance</span><span class="headingEndMark"> — </span>The burden of mycobacteria within a pulmonary cavity is estimated to be between 10<sup>7</sup> and 10<sup>9</sup> colony-forming unit/mL [<a href="#rid60">60</a>]. For many years, it was believed that <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> (INH) kills the largest subpopulation of bacilli that are in the exponential phase of growth during the first three days of therapy and that, once this population is depleted, INH is no longer effective. An in vitro infection model has shown that, while most early bactericidal activity does decline by 72 hours, the outcome is best explained by the emergence of drug-resistant isolates, which were undergoing exponential-phase growth [<a href="#rid61">61</a>].</p><p>Resistance to INH may be conferred by alterations in the <em>katG</em> and/or <em>inhA</em> genes. Mutations to <em>katG</em> and/or <em>inhA</em> account for 85 to 90 percent of INH resistance reported by the CDC Molecular Detection of Drug Resistance (MDDR) service [<a href="#rid62">62</a>].</p><p>It was observed in the 1950s that strains of <em>M. tuberculosis</em> that do not produce catalase are usually resistant to INH [<a href="#rid63">63</a>]. This finding led to the hypothesis that INH is a prodrug requiring alteration by catalase into its functional form. Subsequently, it was shown that deletion or mutation in the catalase gene (<em>katG</em>) is responsible for 10 to 25 percent of cases of INH resistance [<a href="#rid64">64,65</a>]. Such a mutation would also decrease the survival of the organism, were it not for compensatory hyperexpression of alkyl hydroperoxidase to protect against the toxic effect of organic peroxides [<a href="#rid66">66</a>].</p><p>Strong evidence favors an integral role of <em>inhA</em> in determining INH susceptibility; one <em>inhA</em> enzyme with introduced point mutations was 17 times more resistant to inhibition by INH than the wild-type enzyme [<a href="#rid67">67</a>]. This gene encodes a protein long-chain enoyl-acyl carrier protein reductase, which is involved in the synthesis of mycolic acid, an important cell wall component of mycobacteria [<a href="#rid68">68</a>]. Presumably, INH is activated by catalase and then binds to the <em>inhA</em> protein to inhibit cell wall synthesis [<a href="#rid68">68</a>]. Upregulation of <em>inhA </em>can overwhelm the inhibitory capacity of INH, and mutations in <em>inhA</em> can prevent binding of INH and therefore lead to drug resistance [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Rifampin resistance</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> is the cornerstone of short-course chemotherapy regimens, so rifampin resistance prolongs and complicates treatment. Rifampin is thought to act against <em>M. tuberculosis</em> by binding to ribonucleic acid (RNA) polymerase, resulting in interference with transcription and RNA prolongation. Mutations in the <em>rpoB</em> gene, which encodes the beta chain of mycobacterial RNA polymerase, have been found to cause clinical rifampin resistance [<a href="#rid70">70,71</a>].</p><p>In one report, a mutation in <em>rpoB</em> was identified in 64 of 66 resistant organisms from diverse geographic areas but in none of 56 sensitive organisms [<a href="#rid72">72</a>]. <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> resistance may be detected as quickly as four hours after receipt of a sputum sample by the laboratory using the GeneXpert system available in most United States public health and in many hospital TB laboratories. The CDC's MDDR service also detects <em>rpoB</em> mutations associated with rifampin resistance [<a href="#rid62">62</a>]. These rapid assays can facilitate institution of proper therapy for patients and contacts within days of clinical presentation [<a href="#rid73">73-75</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Pyrazinamide resistance</span><span class="headingEndMark"> — </span>Conventional methods used to determine <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">pyrazinamide</a> (PZA) resistance are complex and require acidic media (broth-based only), which may adversely affect growth [<a href="#rid76">76</a>]. PZA is a prodrug that is converted to its active form, pyrazinoic acid, by the enzyme pyrazinamidase. PZA resistance is due to any of a number of mutations in the gene <em>pncA</em>, which encodes this enzyme [<a href="#rid77">77,78</a>]. In one report, 33 of 38 PZA-resistant clinical isolates had <em>pncA</em> mutations; among the five strains that did not contain <em>pncA</em> mutations, four were falsely resistant and one had only borderline resistance [<a href="#rid78">78</a>].</p><p>Among nearly 80,000 cases of TB in the United States between 1999 and 2009, PZA resistance was observed in 2.7 percent of cases [<a href="#rid79">79</a>]. Associated characteristics included age 0 to 24 years, Hispanic ethnicity, extrapulmonary disease, and normal chest radiograph. Inversely associated characteristics included Asian and Black race.</p><p class="headingAnchor" id="H19"><span class="h2">Ethambutol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">Ethambutol</a> inhibits mycobacterial cell wall biosynthesis. Ethambutol resistance in approximately 60 percent of organisms is due to amino acid replacements at position 306 of an arabinosyl transferase encoded by the <em>embB</em> gene [<a href="#rid80">80</a>]. Arabinosyl transferase is an enzyme that polymerizes arabinose into arabinan and then arabinogalactan, a mycobacterial cell wall constituent [<a href="#rid81">81,82</a>]. Increased production of arabinosyl transferase overwhelms the effects of ethambutol. (See  <a class="medical medical_review" href="/z/d/html/478.html" rel="external">"Ethambutol: An overview"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Streptomycin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">Streptomycin</a> acts by inhibiting microbial mRNA translation. Resistance is conferred by mutations in the <em>rpsL</em> and <em>rrs</em> genes, which affect ribosomal protein S12, or the 16S portion of ribosomal RNA [<a href="#rid83">83,84</a>]. Streptomycin cannot inhibit protein synthesis in mycobacteria with these alterations in ribosomal structure.</p><p class="headingAnchor" id="H21"><span class="h2">Second-line agents</span><span class="headingEndMark"> — </span>Resistance has also been documented in second-line antituberculous drugs including fluoroquinolones and <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">ethionamide</a>.</p><p>Fluoroquinolones inhibit DNA gyrases, which are important in maintaining the proper tertiary structure of DNA. Resistance is caused by mutations in the <em>gyrA </em>and <em>gyrB</em> genes, which encode the target DNA gyrases [<a href="#rid85">85,86</a>]. Specifically, amino acid changes in a subunit of DNA gyrase cause fluoroquinolone resistance in most organisms. Fluoroquinolones are becoming increasingly important in the treatment of TB but, to date, resistance to this class of drugs is relatively uncommon in the United States [<a href="#rid80">80</a>].</p><p><a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">Ethionamide</a> is a nicotinic acid derivative similar in structure to INH. Mutations in the <em>inhA</em> gene are also associated with ethionamide resistance, although catalase mutations (eg, <em>katG</em>) are not [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H392007977"><span class="h1">NEW REGIMENS AND EMERGING RESISTANCE</span><span class="headingEndMark"> — </span>New all-oral regimens for rifampin-resistant TB endorsed by the World Health Organization [<a href="#rid88">88</a>] and the United States Centers for Disease Control and Prevention/Infectious Diseases Society of America [<a href="#rid89">89</a>] are based on a <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">bedaquiline</a> core, as part of a multidrug combination that includes <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a>. (See  <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults"</a>.)</p><p>As these drug regimens are being used worldwide, concern has been raised about the emergence of resistance during treatment:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 70 isolates from 30 patients with multidrug-resistant and extensively drug-resistant TB on bedaquiline-containing regimens who were retrospectively tested for <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">bedaquiline</a> resistance by minimum inhibitory concentration (MIC) and by molecular detection of relevant gene mutations, six patients developed progressive increases in bedaquiline MICs in 7H11 medium during therapy associated with increasing MICs to <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> and characterized by emergence of specific mutations in <em>Rv0678</em>, and five patients developed bedaquiline resistance during treatment by phenotypic testing using critical drug concentrations [<a href="#rid90">90</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent study characterized a wide diversity of <em>Rv0678</em> mutations in the genomes of clinical isolates from hospitals in KwaZulu-Natal, South Africa, demonstrating <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">bedaquiline</a> and <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> resistance, with evidence of onward transmission [<a href="#rid91">91</a>]. </p><p></p><p>These findings suggest that with use of multidrug TB treatment regimens for drug-resistant TB, routine monitoring for phenotypic and molecular resistance to <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">bedaquiline</a> and <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> should be performed where possible to prevent emergence of resistance and treatment failure, especially in patients with delayed culture conversion [<a href="#rid92">92</a>]. (See  <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults"</a>.)</p><p class="headingAnchor" id="H795186906"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111822.html" rel="external">"Society guideline links: Diagnosis and treatment of tuberculosis"</a>.)</p><p class="headingAnchor" id="H7698631"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, and resistance to commonly used antituberculous drugs is increasing. (See <a class="local">'Introduction'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The term "drug-resistant TB" refers to cases of TB caused by an isolate of <em>Mycobacterium tuberculosis</em> that is resistant to one of the first-line anti-TB drugs: <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">pyrazinamide</a>, <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, or <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>. The term "multidrug-resistant TB" (MDR-TB) refers to an isolate of <em>M. tuberculosis</em> that is resistant to at least isoniazid and rifampin and possibly additional chemotherapeutic agents. (See <a class="local">'Definitions for tuberculosis drug resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary drug resistance is said to occur in a patient who has never received anti-TB therapy. Secondary drug resistance refers to the development of resistance during or following chemotherapy in patients who had previously had drug-susceptible TB. (See <a class="local">'Definitions for tuberculosis drug resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The World Health Organization has estimated at least 500,000 cases of MDR-TB occur annually worldwide; it likely that ≤30,000 are treated appropriately. China, India, and Russia (and the countries of the former Soviet Union) are estimated to carry the highest number of MDR-TB cases. (See <a class="local">'Worldwide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the United States, drug resistance began emerging in some regions in the early 1990s. The prevalence of drug-resistant TB in the United States decreased between the 1990s and mid-2000s and since then has remained stable. Factors leading to development of resistance include inadequate course of treatment, poorly supervised treatment programs, and poor infection control programs. (See <a class="local">'United States'</a> above and <a class="local">'Risk factors for development of drug resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for MDR-TB are summarized in the following table  (<a class="graphic graphic_table graphicRef108729" href="/z/d/graphic/108729.html" rel="external">table 4</a>); these include prior episode of TB treatment, progressive clinical and/or radiographic findings while on TB therapy, residence in or travel to a region with high prevalence of drug-resistant TB  (<a class="graphic graphic_figure graphicRef116433" href="/z/d/graphic/116433.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef116434" href="/z/d/graphic/116434.html" rel="external">figure 2</a>), and/or exposure to an individual with known or suspected infectious drug-resistant TB. (See <a class="local">'Risk factors for development of drug resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Understanding the molecular basis for drug resistance in <em>M. tuberculosis</em> is gaining importance in rapid diagnostic testing and development of therapeutic strategies against drug-resistant TB. The availability of tools including the GeneXpert system and molecular determination of drug resistance by the United States Centers for Disease Control and Prevention hold promise for more rapid diagnosis and tailoring of drug therapy for patients and contacts. (See <a class="local">'Molecular basis of drug-resistant tuberculosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring for emergence of drug resistance may be critical in new treatment regimens for rifamycin and MDR/extensively drug-resistant-TB to prevent treatment failure and transmission of drug-resistant infection. (See <a class="local">'New regimens and emerging resistance'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Behr MA, Kaufmann E, Duffin J, et al. Latent Tuberculosis: Two Centuries of Confusion. Am J Respir Crit Care Med 2021; 204:142.</a></li><li><a class="nounderline abstract_t">Zignol M, Dean AS, Falzon D, et al. Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance. N Engl J Med 2016; 375:1081.</a></li><li class="breakAll">World Health Organization. Global tuberculosis report 2021. https://www.who.int/publications/i/item/9789240037021 (Accessed on November 08, 2021).</li><li class="breakAll">WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world, report no. 4 http://www.who.int/tb/features_archive/drsreport_launch_26feb08/en/index.html (Accessed on April 29, 2008).</li><li><a class="nounderline abstract_t">Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90:111.</a></li><li class="breakAll">World Health Organization. Global tuberculosis report 2020. https://www.who.int/tb/publications/global_report/en/ (Accessed on December 08, 2020).</li><li><a class="nounderline abstract_t">Dean AS, Tosas Auguet O, Glaziou P, et al. 25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward. Lancet Infect Dis 2022; 22:e191.</a></li><li><a class="nounderline abstract_t">Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012; 366:2161.</a></li><li><a class="nounderline abstract_t">Poudel A, Nakajima C, Fukushima Y, et al. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated in Nepal. Antimicrob Agents Chemother 2012; 56:2831.</a></li><li><a class="nounderline abstract_t">Taype CA, Agapito JC, Accinelli RA, et al. Genetic diversity, population structure and drug resistance of Mycobacterium tuberculosis in Peru. Infect Genet Evol 2012; 12:577.</a></li><li><a class="nounderline abstract_t">Tessema B, Beer J, Emmrich F, et al. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis 2012; 12:37.</a></li><li><a class="nounderline abstract_t">Singla N, Singla R, Jain G, et al. Tuberculosis among household contacts of multidrug-resistant tuberculosis patients in Delhi, India. Int J Tuberc Lung Dis 2011; 15:1326.</a></li><li><a class="nounderline abstract_t">Loewenberg S. India reports cases of totally drug-resistant tuberculosis. Lancet 2012; 379:205.</a></li><li><a class="nounderline abstract_t">Chen L, Li N, Liu Z, et al. Genetic diversity and drug susceptibility of Mycobacterium tuberculosis isolates from Zunyi, one of the highest-incidence-rate areas in China. J Clin Microbiol 2012; 50:1043.</a></li><li><a class="nounderline abstract_t">Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375:1830.</a></li><li class="breakAll">World Health Organization. Global Tuberculosis Control 2011. http://apps.who.int/iris/bitstream/handle/10665/44728/9789241564380_eng.pdf?sequence=1&amp;isAllowed=y (Accessed on August 03, 2018).</li><li><a class="nounderline abstract_t">Lew W, Pai M, Oxlade O, et al. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008; 149:123.</a></li><li><a class="nounderline abstract_t">Mak A, Thomas A, Del Granado M, et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008; 178:306.</a></li><li><a class="nounderline abstract_t">Gler MT, Macalintal LE, Raymond L, et al. Multidrug-resistant tuberculosis among previously treated patients in the Philippines. Int J Tuberc Lung Dis 2011; 15:652.</a></li><li><a class="nounderline abstract_t">Nelson LJ, Talbot EA, Mwasekaga MJ, et al. Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002. Lancet 2005; 366:488.</a></li><li><a class="nounderline abstract_t">Temple B, Ayakaka I, Ogwang S, et al. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis 2008; 47:1126.</a></li><li><a class="nounderline abstract_t">Zignol M, Dean AS, Alikhanova N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis 2016; 16:1185.</a></li><li><a class="nounderline abstract_t">Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283:2537.</a></li><li><a class="nounderline abstract_t">Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328:521.</a></li><li><a class="nounderline abstract_t">Smith SE, Pratt R, Trieu L, et al. Epidemiology of Pediatric Multidrug-Resistant Tuberculosis in the United States, 1993-2014. Clin Infect Dis 2017; 65:1437.</a></li><li><a class="nounderline abstract_t">Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271:665.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Trends in tuberculosis--United States, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:281.</a></li><li><a class="nounderline abstract_t">Moonan PK, Teeter LD, Salcedo K, et al. Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study. Lancet Infect Dis 2013; 13:777.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Trends in tuberculosis - United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:181.</a></li><li class="breakAll">CDC. Reported tuberculosis in the United States, 1995. Center for Disease Control, 1996.</li><li><a class="nounderline abstract_t">Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City--turning the tide. N Engl J Med 1995; 333:229.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2016. https://www.cdc.gov/tb/statistics/reports/2016/pdfs/2016_Surveillance_FullReport.pdf (Accessed on July 25, 2018).</li><li class="breakAll">Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2017. https://www.cdc.gov/tb/statistics/reports/2017/default.htm (Accessed on November 14, 2018).</li><li class="breakAll">Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2013. US Department of Health and Human Services, Atlanta, GA 2013. http://www.cdc.gov/tb/statistics/reports/2013/pdf/report2013.pdf (Accessed on May 04, 2015).</li><li class="breakAll">Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2019. https://www.cdc.gov/tb/statistics/reports/2019/default.htm (Accessed on December 08, 2020).</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Multidrug-resistant tuberculosis in Hmong refugees resettling from Thailand into the United States, 2004-2005. MMWR Morb Mortal Wkly Rep 2005; 54:741.</a></li><li><a class="nounderline abstract_t">Oeltmann JE, Varma JK, Ortega L, et al. Multidrug-resistant tuberculosis outbreak among US-bound Hmong refugees, Thailand, 2005. Emerg Infect Dis 2008; 14:1715.</a></li><li><a class="nounderline abstract_t">Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196 Suppl 1:S86.</a></li><li><a class="nounderline abstract_t">Yang C, Shen X, Peng Y, et al. Transmission of Mycobacterium tuberculosis in China: a population-based molecular epidemiologic study. Clin Infect Dis 2015; 61:219.</a></li><li><a class="nounderline abstract_t">Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994; 149:1359.</a></li><li><a class="nounderline abstract_t">Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA 1993; 270:65.</a></li><li><a class="nounderline abstract_t">Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144:745.</a></li><li><a class="nounderline abstract_t">Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274:945.</a></li><li><a class="nounderline abstract_t">Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179.</a></li><li><a class="nounderline abstract_t">Fujiwara PI, Cook SV, Rutherford CM, et al. A continuing survey of drug-resistant tuberculosis, New York City, April 1994. Arch Intern Med 1997; 157:531.</a></li><li><a class="nounderline abstract_t">Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204:1951.</a></li><li><a class="nounderline abstract_t">Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55:169.</a></li><li><a class="nounderline abstract_t">Dartois V. Drug forgiveness and interpatient pharmacokinetic variability in tuberculosis. J Infect Dis 2011; 204:1827.</a></li><li><a class="nounderline abstract_t">Basu S, Orenstein E, Galvani AP. The theoretical influence of immunity between strain groups on the progression of drug-resistant tuberculosis epidemics. J Infect Dis 2008; 198:1502.</a></li><li class="breakAll">World Health Organization. Laboratory XDR-TB definitions. Meeting of the Global XDR TB Task Force. WHO, Geneva 2006.</li><li><a class="nounderline abstract_t">Beck-Sagué C, Dooley SW, Hutton MD, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 1992; 268:1280.</a></li><li><a class="nounderline abstract_t">Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992; 117:177.</a></li><li><a class="nounderline abstract_t">Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326:1514.</a></li><li><a class="nounderline abstract_t">Ikeda RM, Birkhead GS, DiFerdinando GT Jr, et al. Nosocomial tuberculosis: an outbreak of a strain resistant to seven drugs. Infect Control Hosp Epidemiol 1995; 16:152.</a></li><li><a class="nounderline abstract_t">Blumberg HM, Watkins DL, Berschling JD, et al. Preventing the nosocomial transmission of tuberculosis. Ann Intern Med 1995; 122:658.</a></li><li><a class="nounderline abstract_t">Maloney SA, Pearson ML, Gordon MT, et al. Efficacy of control measures in preventing nosocomial transmission of multidrug-resistant tuberculosis to patients and health care workers. Ann Intern Med 1995; 122:90.</a></li><li><a class="nounderline abstract_t">Stroud LA, Tokars JI, Grieco MH, et al. Evaluation of infection control measures in preventing the nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in a New York City hospital. Infect Control Hosp Epidemiol 1995; 16:141.</a></li><li><a class="nounderline abstract_t">Basu S, Andrews JR, Poolman EM, et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 2007; 370:1500.</a></li><li><a class="nounderline abstract_t">Davis JL, Kawamura LM, Chaisson LH, et al. Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. a hypothetical trial. Am J Respir Crit Care Med 2014; 189:1551.</a></li><li><a class="nounderline abstract_t">Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965; 92:687.</a></li><li><a class="nounderline abstract_t">Gumbo T, Louie A, Liu W, et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007; 195:194.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention, Division of Tuberculosis Elimination Laboratory Branch. Laboratory User Guide for U.S. Public Health Laboratories: Molecular Detection of Drug Resistance (MDDR) in Mycobacterium tuberculosis Complex by DNA Sequencing (Version 2.0), June 2012. https://www.cdc.gov/tb/topic/laboratory/MDDRUsersGuide.pdf (Accessed on August 03, 2018).</li><li><a class="nounderline abstract_t">MIDDLEBROOK G. Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report. Am Rev Tuberc 1954; 69:471.</a></li><li><a class="nounderline abstract_t">Heym B, Alzari PM, Honoré N, Cole ST. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1995; 15:235.</a></li><li><a class="nounderline abstract_t">Zhang Y, Heym B, Allen B, et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358:591.</a></li><li><a class="nounderline abstract_t">Sherman DR, Mdluli K, Hickey MJ, et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996; 272:1641.</a></li><li><a class="nounderline abstract_t">Vilchèze C, Wang F, Arai M, et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 2006; 12:1027.</a></li><li><a class="nounderline abstract_t">Rozwarski DA, Grant GA, Barton DH, et al. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998; 279:98.</a></li><li><a class="nounderline abstract_t">Telenti A. Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Thorax 1998; 53:793.</a></li><li><a class="nounderline abstract_t">Donnabella V, Martiniuk F, Kinney D, et al. Isolation of the gene for the beta subunit of RNA polymerase from rifampicin-resistant Mycobacterium tuberculosis and identification of new mutations. Am J Respir Cell Mol Biol 1994; 11:639.</a></li><li><a class="nounderline abstract_t">Miller LP, Crawford JT, Shinnick TM. The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38:805.</a></li><li><a class="nounderline abstract_t">Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341:647.</a></li><li><a class="nounderline abstract_t">Kapur V, Li LL, Iordanescu S, et al. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994; 32:1095.</a></li><li><a class="nounderline abstract_t">Telenti A, Imboden P, Marchesi F, et al. Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother 1993; 37:2054.</a></li><li><a class="nounderline abstract_t">Nash KA, Gaytan A, Inderlied CB. Detection of rifampin resistance in Mycobacterium tuberculosis by use of a rapid, simple, and specific RNA/RNA mismatch assay. J Infect Dis 1997; 176:533.</a></li><li><a class="nounderline abstract_t">Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 1988; 32:1002.</a></li><li><a class="nounderline abstract_t">Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996; 2:662.</a></li><li><a class="nounderline abstract_t">Scorpio A, Lindholm-Levy P, Heifets L, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41:540.</a></li><li><a class="nounderline abstract_t">Kurbatova EV, Cavanaugh JS, Dalton T, et al. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009. Clin Infect Dis 2013; 57:1081.</a></li><li><a class="nounderline abstract_t">Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79:3.</a></li><li><a class="nounderline abstract_t">Telenti A, Philipp WJ, Sreevatsan S, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 1997; 3:567.</a></li><li><a class="nounderline abstract_t">Belanger AE, Besra GS, Ford ME, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci U S A 1996; 93:11919.</a></li><li><a class="nounderline abstract_t">Nair J, Rouse DA, Bai GH, Morris SL. The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis. Mol Microbiol 1993; 10:521.</a></li><li><a class="nounderline abstract_t">Honoré N, Cole ST. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 1994; 38:238.</a></li><li><a class="nounderline abstract_t">Cambau E, Sougakoff W, Jarlier V. Amplification and nucleotide sequence of the quinolone resistance-determining region in the gyrA gene of mycobacteria. FEMS Microbiol Lett 1994; 116:49.</a></li><li><a class="nounderline abstract_t">Cambau E, Sougakoff W, Besson M, et al. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994; 170:479.</a></li><li><a class="nounderline abstract_t">Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263:227.</a></li><li class="breakAll">World Health Organization. WHO 2019 consolidated guidelines on drug-resistant tuberculosis treatment. https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf?ua=1 (Accessed on January 12, 2021).</li><li><a class="nounderline abstract_t">Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2019; 200:e93.</a></li><li><a class="nounderline abstract_t">Ghodousi A, Rizvi AH, Baloch AQ, et al. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Nimmo C, Millard J, van Dorp L, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe 2020; 1:e165.</a></li><li><a class="nounderline abstract_t">Andres S, Merker M, Heyckendorf J, et al. Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon. Am J Respir Crit Care Med 2020; 201:1564.</a></li></ol></div><div id="topicVersionRevision">Topic 8027 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Latent Tuberculosis: Two Centuries of Confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27626523" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27626523" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27626523" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22423162" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22423162" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35248168" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22670902" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : National survey of drug-resistant tuberculosis in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22450970" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated in Nepal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22342744" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Genetic diversity, population structure and drug resistance of Mycobacterium tuberculosis in Peru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22325147" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22283889" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tuberculosis among household contacts of multidrug-resistant tuberculosis patients in Delhi, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22272391" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : India reports cases of totally drug-resistant tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22205809" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Genetic diversity and drug susceptibility of Mycobacterium tuberculosis isolates from Zunyi, one of the highest-incidence-rate areas in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20488523" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20488523" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626051" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18511706" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21756517" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Multidrug-resistant tuberculosis among previously treated patients in the Philippines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16084258" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18808360" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27397590" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10815117" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8381207" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The emergence of drug-resistant tuberculosis in New York City.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28633501" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Epidemiology of Pediatric Multidrug-Resistant Tuberculosis in the United States, 1993-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8080502" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Nationwide survey of drug-resistant tuberculosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18354371" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Trends in tuberculosis--United States, 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23759447" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22437911" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Trends in tuberculosis - United States, 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22437911" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Trends in tuberculosis - United States, 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791840" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tuberculosis in New York City--turning the tide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791840" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Tuberculosis in New York City--turning the tide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791840" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tuberculosis in New York City--turning the tide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791840" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tuberculosis in New York City--turning the tide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791840" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tuberculosis in New York City--turning the tide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16079738" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Multidrug-resistant tuberculosis in Hmong refugees resettling from Thailand into the United States, 2004-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18976554" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Multidrug-resistant tuberculosis outbreak among US-bound Hmong refugees, Thailand, 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17624830" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : HIV infection and multidrug-resistant tuberculosis: the perfect storm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25829000" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Transmission of Mycobacterium tuberculosis in China: a population-based molecular epidemiologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8173779" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8510299" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928942" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7674524" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Eleven years of community-based directly observed therapy for tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8139628" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9066457" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A continuing survey of drug-resistant tuberculosis, New York City, April 1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22021624" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22467670" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22021619" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Drug forgiveness and interpatient pharmacokinetic variability in tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18816192" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The theoretical influence of immunity between strain groups on the progression of drug-resistant tuberculosis epidemics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18816192" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The theoretical influence of immunity between strain groups on the progression of drug-resistant tuberculosis epidemics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1507374" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1616211" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1304721" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7608502" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Nosocomial tuberculosis: an outbreak of a strain resistant to seven drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7702227" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Preventing the nosocomial transmission of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993001" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy of control measures in preventing nosocomial transmission of multidrug-resistant tuberculosis to patients and health care workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7608500" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Evaluation of infection control measures in preventing the nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in a New York City hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17964351" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24869625" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. a hypothetical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5321145" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Present aspects of bacterial resistance in tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17191164" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17191164" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13138881" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7746145" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1501713" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8658136" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16906155" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9417034" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10319064" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7946393" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Isolation of the gene for the beta subunit of RNA polymerase from rifampicin-resistant Mycobacterium tuberculosis and identification of new mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8031050" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The rpoB gene of Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8095569" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8027320" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8257122" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9237726" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Detection of rifampin resistance in Mycobacterium tuberculosis by use of a rapid, simple, and specific RNA/RNA mismatch assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3142340" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640557" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9055989" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23840002" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10645439" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9142129" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8876238" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7968530" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8192450" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Streptomycin resistance in mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8132154" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Amplification and nucleotide sequence of the quinolone resistance-determining region in the gyrA gene of mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8035042" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8284673" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8284673" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31729908" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31262765" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32803174" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32053752" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
